1.25Open1.25Pre Close0 Volume7 Open Interest3.00Strike Price0.00Turnover143.04%IV4.42%PremiumDec 20, 2024Expiry Date1.07Intrinsic Value100Multiplier28DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type0.8358Delta0.1537Gamma3.26Leverage Ratio-0.0074Theta0.0016Rho2.72Eff Leverage0.0028Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet